Journal
NEW ENGLAND JOURNAL OF MEDICINE
Volume 361, Issue 3, Pages 255-263Publisher
MASSACHUSETTS MEDICAL SOC
DOI: 10.1056/NEJMoa0809437
Keywords
-
Categories
Funding
- National Institute on Aging [P30-AG19610, R01-AG031581]
- National Institute of Mental Health [R01-MH057899]
- Alzheimer's Association [IIRG-98-078]
- Arizona Alzheimer's Consortium
- State of Arizona
Ask authors/readers for more resources
Background The APOE epsilon 4 allele is associated with the risk of late-onset Alzheimer's disease. The age at which memory decline diverges among persons who are homozygous for the APOE epsilon 4 allele, those who are heterozygous for the allele, and noncarriers is unknown. Methods Using local advertisements, we recruited cognitively normal subjects between the ages of 21 and 97 years, who were grouped according to their APOE epsilon 4 status. We then followed the subjects with longitudinal neuropsychological testing. Anyone in whom mild cognitive impairment or dementia developed during follow-up was excluded. We compared the rates of decline in predetermined cognitive measures between carriers and noncarriers of the APOE epsilon 4 allele, using a mixed model for longitudinal change with age. Results We analyzed 815 subjects: 317 APOE epsilon 4 carriers (79 who were homozygous for the APOE epsilon 4 allele and 238 who were heterozygous) and 498 noncarriers. Carriers, as compared with noncarriers, were generally younger (mean age, 58.0 vs. 61.4 years; P<0.001) and were followed for a longer period (5.3 vs. 4.7 years, P = 0.01), with an equivalent duration of formal education (15.4 years) and proportion of women (69%). Longitudinal decline in memory in carriers began before the age of 60 years and showed greater acceleration than in noncarriers (P = 0.03), with a possible allele-dose effect (P = 0.008). We observed similar although weaker effects on measures of visuospatial awareness and general mental status. Conclusions Age-related memory decline in APOE epsilon 4 carriers diverges from that of noncarriers before the age of 60 years, despite ongoing normal clinical status.
Authors
I am an author on this paper
Click your name to claim this paper and add it to your profile.
Reviews
Recommended
No Data Available